BUPROPION VS PLACEBO IN THE TREATMENT OF PATHOLOGICAL GAMBLING

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。病态赌博（PG）已成为主要的健康问题，特别是随着赌博机会的激增。尽管它很重要，但很少有被证实有效的治疗方案。本项目的目的是对安非他酮- sr与安慰剂治疗PG进行随机双盲比较。安非他酮用于治疗注意缺陷多动障碍（ADHD）的疗效，以及PG与ADHD的临床相似性，将被使用。这项研究将是同类研究中的第一项，并有可能为支持一种新的PG治疗方法的有效性提供试点数据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pathological gambling (PG) has become a major health concern, particularly as gambling opportunities have proliferated. Despite its importance, there are few treatment options with proven efficacy. The goal of this project is to conduct a randomized, double-blind comparison of bupropion-SR versus placebo in the treatment of PG. Bupropion will be used because of its reported efficacy in treating attention-deficit hyperactivity disorder (ADHD), and clinical similarities between PG and ADHD. This study will be one of the first of its kind, and has the potential to provide pilot data supporting the efficacy of a novel treatment for PG.